Tag Archives: AstraZeneca’s Baxdrostat Achieves Strong Blood Pressure Reduction in Phase III Bax24 Trial for Resistant Hypertension

AstraZeneca Reports Positive Phase III Bax24 Results, Reinforcing Baxdrostat’s Potential as a Novel Treatment for Hard-to-Control Hypertension

(IN BRIEF) AstraZeneca reported positive Phase III Bax24 trial results showing that baxdrostat achieved a significant and clinically meaningful reduction in 24-hour ambulatory systolic blood pressure in patients with treatment-resistant hypertension. The once-daily oral therapy was well tolerated and maintained … Read the full press release